Radiology and Oncology最新文献

筛选
英文 中文
Gender impact on quality of life in colorectal cancer survivors. 性别对结直肠癌幸存者生活质量的影响
IF 2.2 4区 医学
Radiology and Oncology Pub Date : 2025-04-11 eCollection Date: 2025-09-01 DOI: 10.2478/raon-2025-0023
Aleksandra Grbic, Majda Causevic, Sara Brodaric, Mojca Birk, Irena Oblak
{"title":"Gender impact on quality of life in colorectal cancer survivors.","authors":"Aleksandra Grbic, Majda Causevic, Sara Brodaric, Mojca Birk, Irena Oblak","doi":"10.2478/raon-2025-0023","DOIUrl":"10.2478/raon-2025-0023","url":null,"abstract":"<p><strong>Background: </strong>The aim of the study was to evaluate gender-specific differences in the quality of life (QoL) and late effects among colorectal cancer patients during the first two years after treatment, to inform and improve long-term follow-up care and clinical management strategies.</p><p><strong>Patients and methods: </strong>A total of 239 colorectal cancer patients were included, 56% males and 44% females, mostly in the age range 60-69 years. They were treated at the Institute of Oncology Ljubljana, during the time period from 1<sup>st</sup> September 2023 to 1<sup>st</sup> May 2024. In addition to demographic data, we included clinical data on disease and outcomes collected using the standardized quality of life questionnaires of European Organization for Research and Treatment of Cancer (EORTC) named EORTC QLQ-30 and EORTC QLQ-CR29 for colorectal cancer, respectively.</p><p><strong>Results: </strong>Females were more likely to experience emotional problems (p = 0.002), higher levels of fatigue (p < 0.001), insomnia (p = 0.015), nausea and vomiting (p = 0.007), which may also be associated with poorer appetite in females. Males reported better body image than female (p = 0.047), lower levels of anxiety (p = 0.029), less frequently reported perceived weight loss or gain (p = 0.010). Male reported more stool frequency (p = 0.045), and also had more sever dysuria compared to female (p = 0.008).</p><p><strong>Conclusions: </strong>The results provide the opportunity to improve the clinical management of long-term follow-up and care planning, taking into consideration the gender-specific needs of colorectal cancer survivors.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":" ","pages":"457-465"},"PeriodicalIF":2.2,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12441880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the severity of microvascular invasion in hepatocellular carcinoma, by probing the combination of enhancement modes and growth patterns through magnetic resonance imaging. 磁共振成像增强模式与生长模式的结合评价肝细胞癌微血管浸润的严重程度。
IF 2.2 4区 医学
Radiology and Oncology Pub Date : 2025-04-11 eCollection Date: 2025-06-01 DOI: 10.2478/raon-2025-0021
Yanzhuo Li, Sijie Li, Yan Lei, Lianlian Liu, Bin Song
{"title":"Evaluating the severity of microvascular invasion in hepatocellular carcinoma, by probing the combination of enhancement modes and growth patterns through magnetic resonance imaging.","authors":"Yanzhuo Li, Sijie Li, Yan Lei, Lianlian Liu, Bin Song","doi":"10.2478/raon-2025-0021","DOIUrl":"10.2478/raon-2025-0021","url":null,"abstract":"<p><strong>Background: </strong>Microvascular invasion (MVI), particularly its severity, correlates with prognosis in hepatocellular carcinoma (HCC), however, it remains uncertain which imaging traits are associated with MVI grades. Predicting MVI status precisely pre-surgery assists clinicians in making optimal treatment decisions.</p><p><strong>Patients and methods: </strong>213 HCC patients with surgically confirmed were assigned into three groups based on the severity of MVI (M0, M1, and M2). Clinical and imaging features were compared between each group. Univariate and multivariate analyses were used to identify the significant variables associated with MVI severity. Subsequently, nomograms were constructed to estimate MVI and its M2 grade by crucial factors. Nomograms were assessed for accuracy, clinical value, and efficacy using the area under the curve (AUC), calibration curve, and decision curve analysis (DCA).</p><p><strong>Results: </strong>Four factors associated with MVI (P < 0.05) were related, including non-solitary growth types, no/mini enhanced mode, peritumoral enhancement on arterial phase, and peritumoral hypointensity on hepatobiliary phase. Only the ratio of the maximum and minimum tumor diameter (Max/Min-R), confluent multinodule growth type, and non-washin/washout enhanced modes of those MVI-positive patients showed a strong correlation with M2 grade. The areas under the receiver operating characteristic (ROC) curves were 0.885 (95% confidence intervals [CI]: 0.833-0.937) in identifying MVI and 0.805 (95% CI: 0.703-0.908) in predicting its M2 grade, respectively. The nomograms demonstrated a high goodness-of-fit and clinical benefits in DCA and calibration curve.</p><p><strong>Conclusions: </strong>Enhancement modes and tumor growth patterns of preoperative MRI were independent risk factors of MVI severity, which were valuable for facilitating individualized decision-making.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":" ","pages":"183-192"},"PeriodicalIF":2.2,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality of life of women with recurrent vulvar cancer treated with electrochemotherapy. 化疗治疗复发性外阴癌妇女的生活质量。
IF 2.2 4区 医学
Radiology and Oncology Pub Date : 2025-03-19 eCollection Date: 2025-06-01 DOI: 10.2478/raon-2025-0019
Gregor Vivod, Ines Cilensek, Nina Kovacevic, Gregor Sersa, Maja Cemazar, Sebastjan Merlo
{"title":"Quality of life of women with recurrent vulvar cancer treated with electrochemotherapy.","authors":"Gregor Vivod, Ines Cilensek, Nina Kovacevic, Gregor Sersa, Maja Cemazar, Sebastjan Merlo","doi":"10.2478/raon-2025-0019","DOIUrl":"10.2478/raon-2025-0019","url":null,"abstract":"<p><strong>Background: </strong>The quality of life of patients undergoing oncologic treatment has become an important issue in recent years. Owing to potential mutilation following surgery for vulvar cancer, more conservative approaches have evolved with the integration of new local ablative therapies, such as electrochemotherapy. The aim of this study was to determine the quality of life of women with vulvar cancer recurrence treated with electrochemotherapy for nonpalliative purposes.</p><p><strong>Patients and methods: </strong>Eleven patients with vulvar cancer recurrence were treated with electrochemotherapy from July 2020 to December 2023. Patients completed different questionnaires: the EuroQol - 5 Dimension (EQ-5D), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Vulva Cancer 34 (EORTC QLQ-VU34) and visual analog pain scale (VAS) before and one, three and six months after electrochemotherapy. As a control group, fifteen patients with vulvar cancer recurrence treated with wide local excision completed the EORTC QLQ-C30 and VAS questionnaires before surgery and three and six months after surgery.</p><p><strong>Results: </strong>No significant differences in EQ-5D scores were found between quality of life before electrochemotherapy and at each follow-up visit. A comparison of the EORTC QLQ-C30 scores between the electrochemotherapy and surgery groups showed a significant difference in physical functioning, fatigue, insomnia, and global health status three months after the procedure and in role, cognitive, social functioning and appetite loss six months after the procedure, all of which were in favor of the electrochemotherapy group. The EORTC QLQ-VU34 questionnaire showed improvements in urinary symptoms and symptoms related to scarring and mutilation of the external genitalia in the electrochemotherapy group. The VAS score did not differ significantly between the electrochemotherapy and surgical groups.</p><p><strong>Conclusions: </strong>The study showed that the quality of life after treatment with electrochemotherapy is better in some segments than after surgical treatment.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":" ","pages":"267-276"},"PeriodicalIF":2.2,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient survival after resection of skeletal metastases and endoprosthetic reconstruction: a nation-wide cohort study in a single oncological institution. 骨转移瘤切除和假体内重建后的患者生存率:一项单一肿瘤机构的全国性队列研究。
IF 2.2 4区 医学
Radiology and Oncology Pub Date : 2025-03-19 eCollection Date: 2025-09-01 DOI: 10.2478/raon-2025-0009
Aljaz Mercun, David Martincic, Blaz Mavcic
{"title":"Patient survival after resection of skeletal metastases and endoprosthetic reconstruction: a nation-wide cohort study in a single oncological institution.","authors":"Aljaz Mercun, David Martincic, Blaz Mavcic","doi":"10.2478/raon-2025-0009","DOIUrl":"10.2478/raon-2025-0009","url":null,"abstract":"<p><strong>Background: </strong>The aim of this nation-wide 2009-2021 cohort study was to analyze postoperative survival of patients with resected appendicular skeletal metastases and endoprosthetic reconstruction in comparison to sarcoma patients and non-oncological reconstructions.</p><p><strong>Patients and methods: </strong>A single institution nation-wide cohort of 144 consecutive patients with tumor endoprosthetic reconstructions (32 resected metastases, 73 resected sarcomas, 39 non-oncological) were stratified into histopathological groups according to the 2013-SPRING prediction model. Their survival was analyzed with the Kaplan-Meier method and Cox regression.</p><p><strong>Results: </strong>The observed patient survival rates after wide resection of fast/moderate/slow growing metastases were 25/55/88% at 2 years and 10/30/83% at 5 years, while in sarcomas the observed survival rates were 80% at 2 years and 69% at 5 years. Estimated mean postoperative survival after resection of skeletal metastases was significantly shorter in comparison to sarcomas (4.6 years vs. 9.1 years, log-rank p < 0.001). Predictors of worse patient survival included higher age, pathologic fracture or >1 metastasis, diagnostic group fast-growing metastases and higher preoperative C-reactive protein (CRP).</p><p><strong>Conclusions: </strong>Wide resection and endoprosthetic reconstruction offer a reliable solution in selected patients with skeletal metastases. Higher age, fast-growing metastases (from bladder cancer, colorectal, hepatocellular, lung cancer, malignant melanoma, unknown origin), pathologic fracture or >1 metastasis and elevated CRP predict shorter patient survival and may represent a relative contraindication in this regard.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":" ","pages":"450-456"},"PeriodicalIF":2.2,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12441881/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictive value of pretreatment peripheral blood N/CD4 and N/CD8 ratios for the efficacy of radiotherapy for esophageal cancer. 预处理外周血N/CD4和N/CD8比值对食管癌放疗疗效的预测价值。
IF 2.2 4区 医学
Radiology and Oncology Pub Date : 2025-03-19 eCollection Date: 2025-06-01 DOI: 10.2478/raon-2025-0015
Yu-Rong Jiang, Yu-Ting Su, Jing Hu, Yan Ding, Lu Wang, Zi-Yu Wang, Wan-Ying Sheng, Yi-Xu Fan, Liang-Mei Chu, Yu-Fei Yang, Yi Wen, Miao Han, Si-Yuan Zhou, Chun-Hua Dai, Xu Wang
{"title":"Predictive value of pretreatment peripheral blood N/CD4 and N/CD8 ratios for the efficacy of radiotherapy for esophageal cancer.","authors":"Yu-Rong Jiang, Yu-Ting Su, Jing Hu, Yan Ding, Lu Wang, Zi-Yu Wang, Wan-Ying Sheng, Yi-Xu Fan, Liang-Mei Chu, Yu-Fei Yang, Yi Wen, Miao Han, Si-Yuan Zhou, Chun-Hua Dai, Xu Wang","doi":"10.2478/raon-2025-0015","DOIUrl":"10.2478/raon-2025-0015","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to explore the predictive value of pretreatment peripheral blood immune cell subsets in analyzing the outcomes of patients who underwent radiation therapy for esophageal cancer at their first visit.</p><p><strong>Patients and methods: </strong>This study included 72 patients with esophageal cancer (EC) treated at Jiangsu University Hospital from December 2021 to December 2023. Among them, 48 were males and 24 were females, with a median age of 64 years (range: 52-98 years). Comprehensive clinical data, laboratory results, and imaging findings were collected to analyze survival differences. The log-rank test was used for univariate analysis to assess the sensitivity of these patients to radiotherapy. The statistically significant and clinically relevant factors identified from the univariate analysis were subsequently incorporated into a Cox proportional hazards regression model for multivariate analysis to investigate the associations between pretreatment peripheral blood immune cell subsets and patient survival.</p><p><strong>Results: </strong>Univariate Cox regression analysis revealed that the Eastern Cooperative Oncology Group (ECOG) score, CD4<sup>+</sup> T-cell ratio, neutrophil-to-CD4<sup>+</sup> T-cell ratio (N/CD4), neutrophil-to-CD8<sup>+</sup> T-cell ratio (N/CD8), and neutrophil-to-B-cell ratio (N/B) were significantly correlated with survival outcomes in patients receiving radiotherapy for tumors. Furthermore, multivariate Cox regression analysis identified N/CD4<sup>+</sup> T cells and N/CD8<sup>+</sup> T cells as critical prognostic indicators for these patients. Receiver operating characteristic curve analysis was employed to evaluate the work characteristics of the subjects, resulting in area under the curve values of 0.763 for both N/CD4 and N/CD8. The analysis also revealed that the optimal cutoff values for N/CD4<sup>+</sup> T cells and N/CD8<sup>+</sup> T cells were 0.01053329 and 0.01184294, respectively.</p><p><strong>Conclusions: </strong>N/CD4 and N/CD8 have emerged as viable prognostic predictors for patients undergoing radiotherapy for EC, offering valuable insights for clinicians to strategize further treatment options. However, the retrospective nature of this study introduces potential bias in assessment, underscoring the necessity for large-scale, prospective, randomized controlled trials to substantiate and validate these findings.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":" ","pages":"257-266"},"PeriodicalIF":2.2,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143658400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac MRI for differentiating chemotherapy-induced cardiotoxicity in sarcoma and breast cancer. 心脏MRI鉴别化疗引起的肉瘤和乳腺癌的心脏毒性。
IF 2.1 4区 医学
Radiology and Oncology Pub Date : 2025-02-27 eCollection Date: 2025-03-01 DOI: 10.2478/raon-2025-0012
El-Sayed H Ibrahim, Lubna Chaudhary, Yee-Chung Cheng, Antonio Sosa, Dayeong An, John Charlson
{"title":"Cardiac MRI for differentiating chemotherapy-induced cardiotoxicity in sarcoma and breast cancer.","authors":"El-Sayed H Ibrahim, Lubna Chaudhary, Yee-Chung Cheng, Antonio Sosa, Dayeong An, John Charlson","doi":"10.2478/raon-2025-0012","DOIUrl":"10.2478/raon-2025-0012","url":null,"abstract":"<p><strong>Background: </strong>Over the past few decades, many studies have focused on anthracyclines effect on the heart (cardiotoxicity), but only a few have focused on sarcoma. In this study, we harness the capabilities of advanced cardiac magnetic resonance imaging (MRI) for characterizing anthracyclines-induced cardiotoxicity in sarcoma and compare the results to those from breast cancer patients.</p><p><strong>Patients and methods: </strong>The patients receive an MRI exam at three timepoints: baseline (pre-treatment), posttreatment, and at 6-months follow-up.</p><p><strong>Results: </strong>The results demonstrated a differential response in sarcoma, characterized by increasing left-ventricular (LV) mass and decreasing right ventricular ejection fraction (RVEF). In all patients, left ventricular ejection fraction (LVEF) remained > 50% at all timepoints. Myocardial strain was always lower than the normal threshold values and showed small changes between different timepoints. Myocardial T2 and extracellular volume (ECV) showed increasing and decreasing patterns, respectively, in sarcoma, which were the opposite patterns of those in breast cancer. While myocardium T1 showed increasing values in breast cancer, T1 in sarcoma increased post-treatment and then decreased at the 6-months follow-up. The results showed inverse correlation between dose and different strain components in sarcoma, which was not the case in breast cancer. Certain myocardial segments showed high correlation coefficients with dose, which may reflect their increased sensitivity to cardiotoxicity.</p><p><strong>Conclusions: </strong>Cardiac MRI proved to be a valuable technique for determining anthracycline-induced changes in cardiac function and myocardial tissue composition in sarcoma and differentiating it against breast cancer. It also provides a comprehensive assessment of heart health at baseline, which is important for risk stratification.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"59 1","pages":"79-90"},"PeriodicalIF":2.1,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11867570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bronchial bacterial colonization and the susceptibility of isolated bacteria in patients with lung malignancy. 肺部恶性肿瘤患者支气管细菌定植及分离细菌的易感性。
IF 2.1 4区 医学
Radiology and Oncology Pub Date : 2025-02-27 eCollection Date: 2025-03-01 DOI: 10.2478/raon-2025-0018
Sabrina Petrovic, Bojana Beovic, Viktorija Tomic, Marko Bitenc, Mateja Marc Malovrh, Vladimir Dimitric, Dane Luznik, Martina Miklavcic, Tamara Bozic, Tina Gabrovec, Aleksander Sadikov, Ales Rozman
{"title":"Bronchial bacterial colonization and the susceptibility of isolated bacteria in patients with lung malignancy.","authors":"Sabrina Petrovic, Bojana Beovic, Viktorija Tomic, Marko Bitenc, Mateja Marc Malovrh, Vladimir Dimitric, Dane Luznik, Martina Miklavcic, Tamara Bozic, Tina Gabrovec, Aleksander Sadikov, Ales Rozman","doi":"10.2478/raon-2025-0018","DOIUrl":"10.2478/raon-2025-0018","url":null,"abstract":"<p><strong>Background: </strong>Postoperative pneumonia (POP) remains a leading cause of mortality following lung surgery. Recent studies have confirmed that the respiratory tract below the vocal cords is not sterile and often harbours potentially pathogenic microorganisms (PPMs), putting patients with lung malignancies at an increased risk for pulmonary infections.</p><p><strong>Patients and methods: </strong>The study analysed 149 patients who underwent bronchoscopy for lung lesions suspected to be lung cancer. Protected specimen brush (PSB) samples were obtained during bronchoscopy prior to any specific treatment. Bacterial identification and antimicrobial susceptibility testing were conducted on the isolated strains.</p><p><strong>Results: </strong>Bacterial colonization was detected in 88.6% of patients, with 21.5% carrying PPMs. Notably, patients with type 2 diabetes exhibited a higher rate of PPM colonization compared to others. Antibiotic susceptibility testing showed no significant differences in efficacy between amoxicillin with clavulanic acid and first-generation cephalosporin in both colonized patients and those with PPMs. Importantly, no multidrug-resistant bacteria were identified.</p><p><strong>Conclusions: </strong>Our findings indicate a slightly lower PPM colonization rate compared to previous studies, possibly due to the unique geographic characteristics of the study population. The absence of significant differences in bacterial susceptibility between the two tested antibiotics highlights the need for further research to refine perioperative infection management strategies.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"59 1","pages":"147-152"},"PeriodicalIF":2.1,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11867552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early-time-point 18F-FDG-PET/CT and other prognostic biomarkers of survival in metastatic melanoma patients receiving immunotherapy. 接受免疫治疗的转移性黑色素瘤患者早期时间点18F-FDG-PET/CT和其他预后生物标志物的生存
IF 2.1 4区 医学
Radiology and Oncology Pub Date : 2025-02-27 eCollection Date: 2025-03-01 DOI: 10.2478/raon-2025-0014
Nezka Hribernik, Katja Strasek, Andrej Studen, Katarina Zevnik, Katja Skalic, Robert Jeraj, Martina Rebersek
{"title":"Early-time-point <sup>18</sup>F-FDG-PET/CT and other prognostic biomarkers of survival in metastatic melanoma patients receiving immunotherapy.","authors":"Nezka Hribernik, Katja Strasek, Andrej Studen, Katarina Zevnik, Katja Skalic, Robert Jeraj, Martina Rebersek","doi":"10.2478/raon-2025-0014","DOIUrl":"10.2478/raon-2025-0014","url":null,"abstract":"<p><strong>Background: </strong>A considerable proportion of metastatic melanoma (mM) patients do not respond to immune checkpoint inhibitors (ICIs). There is a great need to develop noninvasive biomarkers to detect patients, who do not respond to ICIs early during the course of treatment. The aim of this study was to evaluate the role of early [<sup>18</sup>F]2fluoro-2-deoxy-D-glucose PET/CT (<sup>18</sup>F-FDG PET/CT) at week four (W4) and other possible prognostic biomarkers of survival in mM patients receiving ICIs.</p><p><strong>Patients and methods: </strong>. In this prospective noninterventional clinical study, mM patients receiving ICIs regularly underwent <sup>18</sup>F-FDG PET/CT: at baseline, at W4 after ICI initiation, at week sixteen and every 16 weeks thereafter. The tumor response to ICIs at W4 was assessed via modified European Organisation for Research and Treatment of Cancer (EORTC) criteria. Patients with progressive metabolic disease (PMD) were classified into the no clinical benefit group (no-CB), and those with other response types were classified into the clinical benefit group (CB). The primary end point was survival analysis on the basis of the W4 <sup>18</sup>F-FDG PET/CT response. The secondary endpoints were survival analysis on the basis of LDH, the number of metastatic localizations, and immune-related adverse events (irAEs). Kaplan-Meier analysis and univariate Cox regression analysis were used to assess the impact on survival.</p><p><strong>Results: </strong>Overall, 71 patients were included. The median follow-up was 37.1 months (952% CI = 30.1-38.0). Three (4%) patients had only baseline scans due to rapid disease progression and death prior to W4 <sup>18</sup>F-FDG-PET/CT. Fifty-one (72%) patients were classified into the CB group, and 17 (24%) were classified into the no-CB group. There was a statistically significant difference in median overall survival (OS) between the CB group (median OS not reached [NR]; 95% CI = 17.8 months - NR) and the no-CB group (median OS 6.2 months; 95% CI = 4.6 months - NR; p = 0.003). Univariate Cox analysis showed HR of 0.4 (95% CI = 0.18 - 0.72; p = 0.004). median OS was also significantly longer in the group with normal serum LDH levels and the group with irAEs and cutaneous irAEs.</p><p><strong>Conclusions: </strong>Evaluation of mM patients with early <sup>18</sup>F-FDG-PET/CT at W4, who were treated with ICIs, could serve as prognostic imaging biomarkers. Other recognized prognostic biomarkers were the serum LDH level and occurrence of cutaneous irAEs.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"59 1","pages":"43-53"},"PeriodicalIF":2.1,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11867565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of 2D and 3D radiomics features with conventional features based on contrast-enhanced CT images for preoperative prediction the risk of thymic epithelial tumors. 术前胸腺上皮肿瘤风险预测基于CT增强图像的二维和三维放射组学特征与常规特征的比较
IF 2.1 4区 医学
Radiology and Oncology Pub Date : 2025-02-27 eCollection Date: 2025-03-01 DOI: 10.2478/raon-2025-0016
Yu-Hang Yuan, Hui Zhang, Wei-Ling Xu, Dong Dong, Pei-Hong Gao, Cai-Juan Zhang, Yan Guo, Ling-Ling Tong, Fang-Chao Gong
{"title":"Comparison of 2D and 3D radiomics features with conventional features based on contrast-enhanced CT images for preoperative prediction the risk of thymic epithelial tumors.","authors":"Yu-Hang Yuan, Hui Zhang, Wei-Ling Xu, Dong Dong, Pei-Hong Gao, Cai-Juan Zhang, Yan Guo, Ling-Ling Tong, Fang-Chao Gong","doi":"10.2478/raon-2025-0016","DOIUrl":"10.2478/raon-2025-0016","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to develop and validate 2-Dimensional (2D) and 3-Dimensional (3D) radiomics signatures based on contrast-enhanced computed tomography (CECT) images for preoperative prediction of the thymic epithelial tumors (TETs) risk and compare the predictive performance with conventional CT features.</p><p><strong>Patients and methods: </strong>149 TET patients were retrospectively enrolled from January 2016 to December 2018, and divided into high-risk group (B2/B3/TCs, n = 103) and low-risk group (A/AB/B1, n = 46). All patients were randomly assigned into the training (n = 104) and testing (n = 45) set. 14 conventional CT features were collected, and 396 radiomic features were extracted from 2D and 3D CECT images, respectively. Three models including conventional, 2D radiomics and 3D radiomics model were established using multivariate logistic regression analysis. The discriminative performances of the models were demonstrated by receiver operating characteristic (ROC) curves.</p><p><strong>Results: </strong>In the conventional model, area under the curves (AUCs) in the training and validation sets were 0.863 and 0.853, sensitivity was 78% and 55%, and specificity was 88% and 100%, respectively. The 2D model yielded AUCs of 0.854 and 0.834, sensitivity of 86% and 77%, and specificity of 72% and 86% in the training and validation sets. The 3D model revealed AUC of 0.902 and 0.906, sensitivity of 75% and 68%, and specificity of 94% and 100% in the training and validation sets.</p><p><strong>Conclusions: </strong>Radiomics signatures based on 3D images could distinguish high-risk from low-risk TETs and provide complementary diagnostic information.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"59 1","pages":"69-78"},"PeriodicalIF":2.1,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11867572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of selective intra-arterial to standard intravenous administration in percutaneous electrochemotherapy (pECT) for liver tumors. 经皮肝肿瘤化疗(spect)中选择性动脉内给药与标准静脉给药的比较。
IF 2.1 4区 医学
Radiology and Oncology Pub Date : 2025-02-27 eCollection Date: 2025-03-01 DOI: 10.2478/raon-2025-0017
Tim Wilke, Erschad Hussain, Hannah Spallek, Francesca de Terlizzi, Lluis M Mir, Peter Bischoff, Andreas Schäfer, Elke Bartmuß, Matteo Cadossi, Alessandro Zanasi, Michael Pinkawa, Attila Kovács
{"title":"Comparison of selective intra-arterial to standard intravenous administration in percutaneous electrochemotherapy (pECT) for liver tumors.","authors":"Tim Wilke, Erschad Hussain, Hannah Spallek, Francesca de Terlizzi, Lluis M Mir, Peter Bischoff, Andreas Schäfer, Elke Bartmuß, Matteo Cadossi, Alessandro Zanasi, Michael Pinkawa, Attila Kovács","doi":"10.2478/raon-2025-0017","DOIUrl":"10.2478/raon-2025-0017","url":null,"abstract":"<p><strong>Background: </strong>Electrochemotherapy (ECT) is a local nonsurgical effective tumor treatment in the hand of the clinician for the treatment of patients with liver tumors or metastases. The study aimed to test the technical feasibility and safety of intra-arterial (i.a.) bleomycin administration compared to the established intravenous (i.v.) administration in percutaneous electrochemotherapy (pECT). Furthermore, the equivalence hypothesis was tested between the 2 modalities in terms of local short-term response and progression-free survival.</p><p><strong>Patients and methods: </strong>Forty-four patients have been recruited and treated by pECT for hepatocellular carcinoma, cholangiocarcinoma and liver metastatic lesions from cancers of different origin: 18 were treated with standard i.v., 26 with bleomycin i.a. administration.</p><p><strong>Results: </strong>The 2 groups were similar for anagraphic and anamnestic data, as well as for most relevant disease specific characteristics. Technical success of the treatment was obtained in 95% and 100% of patients in i.v. and i.a. groups respectively. Short-term local response was similar in the 2 groups with a slightly higher complete remission (CR) rate in the i.a. group. There were 61.9% CR, 23.8% partial remission (PR), 4.8% stable disease (SD) in the i.v. group, and 80.6%, CR 12.9% PR, 3.2% PD (p = 0.3454). One-year progression free survival was 60% (C.I. 33%-88%) in the i.v. group and 67% (C.I. 42%-91%) in the i.a. group (p = 0.5849).</p><p><strong>Conclusions: </strong>The results of this study confirmed the safety and feasibility of super-selective i.a. bleomycin administration. Analysis of local response and progression free survival confirmed the equivalence hypothesis of the new modality compared to standard i.v. administration in the treatment of primary and secondary liver malignancies by pECT.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"59 1","pages":"100-109"},"PeriodicalIF":2.1,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11867569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信